A cannabinoid manufacturer has sued biotech company Amyris for $881M, amid a fraught 18-months relationship between the companies. Among other allegations, the lawsuit claims Amyris used the partnership to artificially inflate its own value and then leveraged the plaintiff’s trade...
This content is FREE for registered users.
To view this content you need to register as a Weedweek member.
If you are already a member please login below.
DCC’s interstate trade memo: An analysis
This week the California Department of Cannabis Control (DCC) sent a memo to California Attorney General Rob Bonta requesting a legal opinion on whether interstate trade poses a "significant risk...
SCOOP: Kingroll responds to potency fraud suit
In September, WeedWeek published a story which found samples from seven out of seven prominent California pre-roll brands contained less THC than stated on their label. Since then, at least...
Seven ways to see a debt crisis
No one denies that the California cannabiz faces a debt crisis. As insiders described recently to Green Market Report, years of unpaid bills and taxes are building to a “mass...